Cui Yankang, Miao Chenkui, Hou Chao, Wang Zengjun, Liu Bianjiang
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Front Oncol. 2020 Aug 20;10:1436. doi: 10.3389/fonc.2020.01436. eCollection 2020.
Apolipoprotein C1 (APOC1) has been proved to play a critical role in gastric, breast, lung, and pancreatic cancer. However, the relationship between APOC1 and urinary tumors remains unclear. This study aimed to assess the diagnostic and prognostic value of APOC1 in urinary tumors. We performed a pan analysis of APOC1 mRNA expression in urinary cancer using the Gene Expression Profiling Interactive Analysis (GEPIA) database. To further investigate the prognostic value of APOC1 expression in urinary cancers, the Kaplan-Meier plotter database was used. Furthermore, we collected the tumor and adjacent normal samples of 32 ccRCC patients to perform qRT-PCR and western blotting assays. A total of 72 cases with ccRCC were analyzed using tissue microarrays (TMAs). Our results based on Kaplan-Meier plotter database indicated that a high expression of APOC1 may lead to poor overall survival (OS, = 0.0019) in patients with ccRCC. Furthermore, the cancer stages and tumor grade of ccRCC appeared to be strongly linked with APOC1 expression according to UALCAN database. Hence, we reached a preliminary conclusion that APOC1 may play a key role in the tumorigenesis and progression of ccRCC. Furthermore, the Kaplan-Meier survival curve analyses of 72 clinical patients indicated that high expression of APOC1 was associated with poor progression-free survival (PFS, = 0.007) and OS ( = 0.022). In addition, univariate Cox regression analysis confirmed the significant relationship between APOC1 expression and survival ( = 0.038). The TMAs analysis in combination with the patients' clinicopathological features was also performed. The expression of APOC1 was found to be significantly correlated with the tumor size ( = 0.018) and histological grade ( = 0.016). In conclusion, the findings of our study suggest that APOC1 may serve as a novel diagnostic and prognostic biomarker for ccRCC. Further evidence on the mechanism of APOC1 promoting tumor progression may transform it to a new therapeutic target for the treatment of ccRCC.
载脂蛋白C1（APOC1）已被证明在胃癌、乳腺癌、肺癌和胰腺癌中起关键作用。然而，APOC1与泌尿系统肿瘤之间的关系仍不清楚。本研究旨在评估APOC1在泌尿系统肿瘤中的诊断和预后价值。我们使用基因表达谱交互分析（GEPIA）数据库对泌尿系统癌症中APOC1 mRNA表达进行了全面分析。为了进一步研究APOC1表达在泌尿系统癌症中的预后价值，我们使用了Kaplan-Meier绘图仪数据库。此外，我们收集了32例透明细胞肾细胞癌（ccRCC）患者的肿瘤及癌旁正常样本，进行qRT-PCR和蛋白质免疫印迹分析。共使用组织芯片（TMA）分析了72例ccRCC病例。我们基于Kaplan-Meier绘图仪数据库的结果表明，APOC1高表达可能导致ccRCC患者总生存期（OS，P = 0.0019）较差。此外，根据UALCAN数据库，ccRCC的癌症分期和肿瘤分级似乎与APOC1表达密切相关。因此，我们初步得出结论，APOC1可能在ccRCC的肿瘤发生和进展中起关键作用。此外，对72例临床患者的Kaplan-Meier生存曲线分析表明，APOC1高表达与无进展生存期（PFS，P = 0.007）和总生存期（P = 0.022）较差相关。此外，单因素Cox回归分析证实了APOC1表达与生存之间的显著关系（P = 0.038）。我们还结合患者的临床病理特征进行了TMA分析。发现APOC1表达与肿瘤大小（P = 0.018）和组织学分级（P = 0.016）显著相关。总之，我们的研究结果表明，APOC1可能作为ccRCC的一种新型诊断和预后生物标志物。关于APOC1促进肿瘤进展机制的进一步证据可能将其转化为ccRCC治疗的新靶点。
